Protein Summary
Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. This gene encodes a member of the kallikrein subfamily of the peptidase S1 family of serine proteases. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. The encoded preproprotein is proteolytically processed to generat ...more
- ENST00000310157
- ENSP00000309148
- ENSG00000167755
- ENST00000376851
- ENSP00000366047
- ENST00000391808
- ENSP00000375684
- ENST00000594641
- ENSP00000470482
- ENST00000597379
- ENSP00000469630
- ENST00000599881
- ENSP00000471948
- PRSS18
- PRSS9
- hK6
- Bssp
- Klk7
- SP59
- PRSS9
- PRSS18
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
gene perturbation | 0.89 | ||
cellular component | 0.7 | ||
PubMedID | 0.7 | ||
biological term | 0.64 | ||
protein domain | 0.58 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 279.29 (req: < 5)
Gene RIFs: 89 (req: <= 3)
Antibodies: 325 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 279.29 (req: >= 5)
Gene RIFs: 89 (req: > 3)
Antibodies: 325 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 17
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0